Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Treatment of non severe Hemophagocytosis Lymphohistiocytosis with ITACITINIB a Phase II prospective trial Ended

2024-513173-44-00 Adults patients having non severe HLH 2022-05-03
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended

2023-508571-37-00 Geographic atrophy (GA) secondary to Age-related Macula 2022-04-29
A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks … Ended

2023-505549-18-00 Hereditary angioedema due to C1-Inhibitor Deficiency (T 2022-04-29
A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment Ended

2023-509141-12-00 Combined Postcapillary and Precapillary Pulmonary Hyper 2022-04-28
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetux… Ended

2024-513082-39-00 Locally Advanced Head & Neck Squamous Cell Carcinoma 2022-04-26
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patien… Ended

2024-513229-22-00 Advanced cutaneous melanoma and Advanced mucosal melano 2022-04-21
Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended

2023-504825-38-00 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN 2022-04-15
Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibili… Ended

2024-517537-40-00 Posttraumatic Stress Disorder 2022-04-06
"OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T… Ended

2023-505097-16-00 Ovarian Neoplasms 2022-04-04
Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1) Ended

2024-510939-21-00 RARA-positive acute myeloid leukemia 2022-04-01
A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non−Small Cell Lung Cancer who have already received chemo… Ended

2023-503756-27-00 Non-Small Cell Lung Cancer (NSCLC) 2022-03-31
SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refra… Ended

2024-515731-29-00 advanced stage hepatocellular carcinoma 2022-03-30
Influence of Argipressin on blood loss during liver resection; a double-blinded, randomized, placebo-controlled trial (ARG-01) Ended

2024-514332-25-00 Hepatic resection due to primary malignant disease, met 2022-03-27
Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negat… Ended

2024-511875-14-00 Pre and post-menopausal women and men with unresectable 2022-03-24
HEMolyse and Organ damage imPROvement in sickle cell disease by VoxElotor Ended

2024-513096-41-00 sickle cell disease 2022-03-24
An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive … Ended

2024-515301-26-00 Muscle-invasive bladder cancer 2022-03-23
A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma … Ended

2023-509917-35-00 Recurrent or Metastatic Squamous Cell Carcinoma of the 2022-03-21
PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanO… Ended

2024-516100-42-00 Melanoma 2022-03-18
A Phase 2 Trial of SCO-101 in combination with FOLFIRI for Patients with Metastatic Colorectal Cancer (mCRC) with acquired Resistance to FOL… Ended

2024-518877-33-00 Metastatic Colorectal Cancer 2022-03-17
Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3… Ended

2024-513518-37-00 Advanced neuroendocrine neoplasias G3 (NEN G3) (excludi 2022-03-15
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAM… Ended

2023-508213-16-00 Multiple Myeloma 2022-03-15
Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0) Ended

2024-519104-27-00 Acute Respiratory Distress Syndrome (ARDS) 2022-03-08
A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder. Ended

2023-506511-17-00 Binge eating disorder 2022-03-07
Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended

2024-512826-26-00 Newly diagnosed, non-metastatic early-stage triple-nega 2022-03-07